What it's for (Indications)
- Bupropion HCl, available in various formulations including immediate-release, sustained-release (SR), and extended-release (XL), is indicated for several distinct clinical conditions.
- The extended-release formulation (e.
- g.
- , Wellbutrin XL) is primarily approved for the treatment of Major Depressive Disorder (MDD) in adults.
- This encompasses both acute treatment of depressive episodes and long-term maintenance therapy to prevent recurrence.
- Furthermore, bupropion XL is specifically indicated for the prevention of Seasonal Affective Disorder (SAD), a type of recurrent major depression that typically manifests during the autumn and winter months.
- Beyond its antidepressant applications, bupropion HCl in its sustained-release formulation (e.
- g.
- , Zyban) is also indicated as an aid to smoking cessation treatment.
- In this capacity, it helps to alleviate nicotine withdrawal symptoms and reduce the urge to smoke, thereby assisting individuals in quitting smoking.
- The distinct pharmacological profile of bupropion allows for its use in these varied indications, offering a therapeutic option particularly beneficial for patients where serotonin modulation alone may be insufficient or undesirable.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | To minimize the risk of seizure, the dose should be increased gradually, not exceeding 100 mg/day in a 3-day period. Bupropion hydrochloride tablets should be swallowed whole and not crushed, divided, or chewed, and may be taken with or without food. The recommended starting dose is 200 mg/day, given as 100 mg twice daily. After 3 days, the dose may be increased to 300 mg/day, given as 100 mg three times daily, with at least 6 hours between successive doses. A maximum dose of 450 mg/day, given in divided doses of not more than 150 mg each (e.g., 100 mg four times daily), may be considered for patients who show no clinical improvement after several weeks of treatment at 300 mg/day. For acute episodes of depression, treatment should generally be continued for several months or longer. |
Safety & Warnings
Common Side Effects
- Common side effects include insomnia, headache, fever, dry mouth, and gastrointestinal upset.
- More serious adverse reactions reported include suicidal thoughts and behaviors (particularly in adolescents and young adults), neuropsychiatric symptoms and suicide risk (especially during smoking cessation treatment), increased risk of seizure, hypertension, activation of mania or hypomania, psychosis and other neuropsychiatric reactions, angle-closure glaucoma, and hypersensitivity reactions.
Serious Warnings
- Black Box Warning: WARNING: SUICIDAL THOUGHTS AND BEHAVIORS SUICIDALITY AND ANTIDEPRESSANT DRUGS. Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials. These trials did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in subjects over age 24; there was a reduction in risk with antidepressant use in subjects aged 65 and older.
- Patients should be closely monitored for suicidal thoughts and behaviors, especially children, adolescents, and young adults, and for neuropsychiatric symptoms and suicide risk during smoking cessation treatment.
- There is an increased risk of seizure, particularly in patients with a history of head trauma, alcohol abuse, or diabetes; the dose should be increased gradually to minimize this risk.
- Other significant warnings include the potential for hypertension, activation of mania or hypomania, psychosis and other neuropsychiatric reactions, angle-closure glaucoma, and hypersensitivity reactions.
- Use during pregnancy and lactation is generally considered contraindicated or requires extreme caution due to potential risks.
How it Works (Mechanism of Action)
Bupropion HCl functions primarily as a norepinephrine-dopamine reuptake inhibitor (NDRI). Its principal mechanism of action involves the selective inhibition of the neuronal reuptake of both norepinephrine and dopamine in the central nervous system. By blocking the reuptake transporters responsible for these monoamine neurotransmitters, bupropion leads to increased extracellular concentrations of norepinephrine and dopamine within the synaptic cleft in various brain regions. This augmentation of monoaminergic neurotransmission is widely believed to be the underlying mechanism for its antidepressant efficacy in Major Depressive Disorder and its preventative effects in Seasonal Affective Disorder. Unlike many other antidepressants, bupropion has minimal to negligible effects on the reuptake of serotonin, distinguishing its pharmacological profile from selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Additionally, bupropion and its active metabolites act as non-competitive antagonists at neuronal nicotinic acetylcholine receptors. This antagonistic effect is thought to significantly contribute to its utility in smoking cessation by interfering with the rewarding effects of nicotine and alleviating withdrawal symptoms. While the precise neurobiological pathways for all its therapeutic effects are complex and remain subjects of ongoing research, the dual inhibition of dopamine and norepinephrine reuptake is considered its most prominent and clinically relevant pharmacological action.